Bo-Yu Du1, Wei Song, Lu Bai, Yan Shen, Shi-Ying Miao, Lin-Fang Wang. 1. National Laboratory of Medical Molecular Biology, School of Basic Medicine, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, PR China.
Abstract
BACKGROUND: Neuroblastoma (NB) is the most common extracranial solid tumor in infants. Currently, the mainstay of NB chemotherapy is combination treatment with some traditional drugs, but these combination regimens are always inefficient. METHODS: The aim of this study was to evaluate the inhibitory effect of a combination of doxorubicin and bortezomib, a novel anticancer drug and the first prote-asome inhibitor approved for the treatment of human malignant tumors, on the proliferation of two human NB cell lines, SK-N-SH and SH-SY5Y. The general mechanism underlying this combined effect was also investigated. Synergistic inhibitory effects on human NB cell proliferation were evaluated using the median-effect principle. The pro-apoptotic effects of these drugs were evaluated using double staining with annexin-V-FITC and propidium iodide. RESULTS: Synergistic inhibitory effects on proliferation were observed when a combination of bortezomib and doxorubicin was applied to cultured NB cells. A similar synergistic effect on apoptosis was also observed when the two drugs were used concurrently, which suggested that the possible mechanism underlying the observed synergistic inhibitory effect might be related to apoptosis. CONCLUSION: The combination of bortezomib and doxorubicin appears to be a promising strategy to treat NB.
BACKGROUND:Neuroblastoma (NB) is the most common extracranial solid tumor in infants. Currently, the mainstay of NB chemotherapy is combination treatment with some traditional drugs, but these combination regimens are always inefficient. METHODS: The aim of this study was to evaluate the inhibitory effect of a combination of doxorubicin and bortezomib, a novel anticancer drug and the first prote-asome inhibitor approved for the treatment of humanmalignant tumors, on the proliferation of two human NB cell lines, SK-N-SH and SH-SY5Y. The general mechanism underlying this combined effect was also investigated. Synergistic inhibitory effects on human NB cell proliferation were evaluated using the median-effect principle. The pro-apoptotic effects of these drugs were evaluated using double staining with annexin-V-FITC and propidium iodide. RESULTS: Synergistic inhibitory effects on proliferation were observed when a combination of bortezomib and doxorubicin was applied to cultured NB cells. A similar synergistic effect on apoptosis was also observed when the two drugs were used concurrently, which suggested that the possible mechanism underlying the observed synergistic inhibitory effect might be related to apoptosis. CONCLUSION: The combination of bortezomib and doxorubicin appears to be a promising strategy to treat NB.
Authors: Marina Yu Skorkina; Elena A Shamray; Victoria A Salo; Anatoly S Buchelnikov; Maxim P Evstigneev Journal: J Bioenerg Biomembr Date: 2017-12-19 Impact factor: 2.945
Authors: Pablo César Ortiz-Lazareno; Alejandro Bravo-Cuellar; José Manuel Lerma-Díaz; Luis Felipe Jave-Suárez; Adriana Aguilar-Lemarroy; Jorge Ramiro Domínguez-Rodríguez; Oscar González-Ramella; Ruth De Célis; Paulina Gómez-Lomelí; Georgina Hernández-Flores Journal: Cancer Cell Int Date: 2014-02-04 Impact factor: 5.722
Authors: Anna S Tsimokha; Valentina A Kulichkova; Elena V Karpova; Julia J Zaykova; Nikolai D Aksenov; Anastasia A Vasilishina; Andrei V Kropotov; Alexey Antonov; Nikolai A Barlev Journal: Oncotarget Date: 2014-06-15